Senior Vice President
Gilead Sciences
Mark Dresser, PhD, joined Gilead Sciences in 2020 as a Senior Vice President. At Gilead, he oversees R&D efforts spanning biomarkers, diagnostics, clinical translational science, clinical pharmacology, pharmacometrics, and clinical bioanalysis. During the COVID-19 pandemic, he also served as Global Development Leader of Gilead’s 2nd Generation Remdesivir program. Previously, Mark served as a Senior Vice President at Denali Therapeutics. As a founding member of its executive team, he built numerous technical departments, including CMC, DMPK, and Toxicology. Under his leadership, Denali advanced five compounds for the treatment of neurodegenerative diseases into clinical development. Mark also played a key role in Denali’s successful IPO in 2017. Before Denali, he held many scientific leadership roles at Genentech/Roche, including Project Team Leader for its Atezolizumab (anti-PDL1) program. He began his career as a Staff Scientist at ALZA Corporation, a Johnson & Johnson company. In addition to his roles in the biopharma industry, Mark serves as a Full Adjunct Professor in the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco, where he co-directs a course on drug discovery, development, and regulation for the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI). Mark served as President of the American Society for Clinical Pharmacology & Therapeutics (ASCPT) during the 2022 – 2023 term, and as an ad hoc member of the National Advisory General Medical Sciences (NAGMS) Council of the NIGMS/NIH in 2023. Endpoints News named him one of 15 industry leaders giving voice and visibility to the LGBTQIA+ community in 2022, and he was recognized as Alumnus of the Year by the UCSF Graduate Division in 2019. He completed his education and training at UCSF, Rensselaer Polytechnic Institute, and the Swiss Federal Institute of Technology.
Disclosure(s): Gilead Sciences: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Oscar B. Hunter Career Award in Therapeutics Lecture
Friday, March 29, 2024
11:00 AM – 11:45 AM MDT